Benjamin Bonavida
Overview
Explore the profile of Benjamin Bonavida including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
175
Citations
4086
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Merenstein A, Obeidat L, Zaravinos A, Bonavida B
Cancers (Basel)
. 2025 Jan;
17(1.
PMID: 39796650
The treatment of cancers with immunotherapies has yielded significant milestones in recent years. Amongst these immunotherapeutic strategies, the FDA has approved several checkpoint inhibitors (CPIs), primarily Anti-Programmed Death-1 (PD-1) and...
2.
Bustamante A, Baritaki S, Zaravinos A, Bonavida B
Cancers (Basel)
. 2024 Sep;
16(18).
PMID: 39335152
Untreated primary carcinomas often lead to progression, invasion and metastasis, a process that involves the epithelial-to-mesenchymal transition (EMT). Several transcription factors (TFs) mediate the development of EMT, including SNAIL1/SNAIL2, TWIST1/TWIST2...
3.
McWhorter R, Bonavida B
Crit Rev Oncog
. 2024 Jul;
29(4):97-125.
PMID: 38989740
Tumor-associated macrophages (TAMs) are the predominant cell infiltrate in the immunosuppressive tumor microenvironment (TME). TAMs are central to fostering pro-inflammatory conditions, tumor growth, metastasis, and inhibiting therapy responses. Many cancer...
4.
Bui I, Bonavida B
Crit Rev Oncog
. 2024 Jul;
29(4):75-95.
PMID: 38989739
We have witnessed in the last decade new milestones in the treatment of various resistant cancers with new immunotherapeutic modalities. These advances have resulted in significant objective durable clinical responses...
5.
Festekdjian T, Bonavida B
Crit Rev Oncog
. 2024 Jul;
29(4):55-73.
PMID: 38989738
We have witnessed the emergence of immunotherapy against various cancers that resulted in significant clinical responses and particularly in cancers that were resistant to chemotherapy. These milestones have ignited the...
6.
Jung M, Bonavida B
Crit Rev Oncog
. 2024 Jul;
29(4):1-17.
PMID: 38989734
Recent advancements in cancer treatment have explored a variety of approaches to address the needs of patients. Recently, immunotherapy has evolved as an efficacious treatment for various cancers resistant to...
7.
8.
Navasardyan I, Zaravinos A, Bonavida B
Cancers (Basel)
. 2024 Jun;
16(11).
PMID: 38893192
The transcription factor Yin Yang 1 (YY1) plays a pivotal role in the pathogenesis of glioblastoma multiforme (GBM), an aggressive form of brain tumor. This review systematically explores the diverse...
9.
Ho M, Bonavida B
Cells
. 2024 May;
13(10.
PMID: 38786085
Innovations in cancer immunotherapy have resulted in the development of several novel immunotherapeutic strategies that can disrupt immunosuppression. One key advancement lies in immune checkpoint inhibitors (ICIs), which have shown...
10.
Dillen A, Bui I, Jung M, Agioti S, Zaravinos A, Bonavida B
Cancers (Basel)
. 2024 Mar;
16(6).
PMID: 38539569
During the last decade, we have witnessed several milestones in the treatment of various resistant cancers including immunotherapeutic strategies that have proven to be superior to conventional treatment options, such...